Workflow
AI suite
icon
Search documents
Plantir stock price tumbles after damming bearish assessment
Finbold· 2025-08-18 16:59
Core Viewpoint - Palantir's stock has faced criticism from Citron Research, which argues that the stock remains overvalued despite a significant drop in price, with a current trading value of $173.10, down 2.3% for the day, but up 130% year to date [1][3]. Group 1: Valuation Concerns - Citron Research claims that Palantir's valuation exceeds its fundamentals, suggesting that if priced similarly to OpenAI, the stock would be around $40, which they do not consider a bargain [4]. - The bearish sentiment is reinforced by comments from OpenAI CEO Sam Altman, who described the AI market as a bubble, raising concerns about sustainable valuations in the sector [3]. Group 2: Insider Selling - Citron highlighted significant insider selling, noting that CEO Alex Karp has sold nearly $2 billion worth of stock over the past two years, labeling him as one of the most aggressive insiders in the tech sector [5]. Group 3: Mixed Analyst Opinions - Despite the bearish outlook from Citron, some analysts have raised their price targets for Palantir, with Wedbush's Dan Ives increasing his target from $160 to $200, citing strong second-quarter results and growing adoption of its AI suite [6]. - Palantir reported a 78% increase in earnings per share, surpassing $1 billion in revenue for the first time, with operating income of $464.4 million and free cash flow of $568.8 million, exceeding Wall Street estimates [7]. - Other analysts, including D.A. Davidson and Mizuho, have also revised their targets upward, indicating a generally positive sentiment among some market participants [8].
Doximity Analysts Increase Their Forecasts After Strong Q1 Earnings
Benzinga· 2025-08-08 15:21
Doximity Inc DOCS reported better-than-expected earnings for the first quarter on Thursday.The company posted quarterly earnings of 36 cents per share which beat the analyst consensus estimate of 30 cents per share. The company reported quarterly sales of $145.913 million which beat the analyst consensus estimate of $139.705 million.Doximity raised its FY2026 sales guidance from $619.000 million-$631.000 million to $628.000 million-$636.000 million.“We began our year with strong profit growth and record eng ...